Cathay Biotech Inc. (SHA:688065)
China · Delayed Price · Currency is CNY 48.20
-0.80 (-1.63%)
Mar 23, 2026, 2:34 PM CST
Cathay Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,295 | 2,819 | 2,067 | 2,332 | 2,296 |
Other Revenue | - | 138.84 | 47.17 | 108.67 | 67.67 |
| 3,295 | 2,958 | 2,114 | 2,441 | 2,363 | |
Revenue Growth (YoY) | 11.41% | 39.91% | -13.39% | 3.28% | 57.86% |
Cost of Revenue | 2,660 | 2,121 | 1,535 | 1,612 | 1,526 |
Gross Profit | 635.09 | 836.44 | 579.23 | 829.2 | 837.21 |
Selling, General & Admin | - | 222 | 221.61 | 232.28 | 175.11 |
Research & Development | - | 233.34 | 189.13 | 187.71 | 133.53 |
Other Operating Expenses | - | 13.83 | 9.21 | -4.09 | 22.94 |
Operating Expenses | - | 472.51 | 413.68 | 422.59 | 337.95 |
Operating Income | 635.09 | 363.93 | 165.55 | 406.61 | 499.25 |
Interest Expense | - | -27.43 | -32.17 | -20.01 | -16.29 |
Interest & Investment Income | - | 160.75 | 219.77 | 236.78 | 229.61 |
Earnings From Equity Investments | - | -8.95 | -7.82 | -3.71 | - |
Currency Exchange Gain (Loss) | - | 36.73 | 29.59 | 82.97 | -14.14 |
Other Non Operating Income (Expenses) | -3.59 | -6.04 | -5.7 | -4.61 | -0.59 |
EBT Excluding Unusual Items | 631.5 | 518.99 | 369.22 | 698.03 | 697.84 |
Gain (Loss) on Sale of Assets | - | 0.42 | -0.01 | 0.07 | - |
Asset Writedown | - | -0.05 | -0.26 | -0.02 | -0.06 |
Other Unusual Items | - | 28.66 | 79.97 | -2.09 | 26.66 |
Pretax Income | 631.5 | 548.02 | 448.92 | 695.99 | 724.45 |
Income Tax Expense | 65.78 | 73.43 | 40.39 | 83.34 | 90.94 |
Earnings From Continuing Operations | 565.72 | 474.59 | 408.54 | 612.65 | 633.51 |
Minority Interest in Earnings | - | 14.37 | -42.01 | -59.39 | -38.79 |
Net Income | 565.72 | 488.96 | 366.52 | 553.27 | 594.72 |
Net Income to Common | 565.72 | 488.96 | 366.52 | 553.27 | 594.72 |
Net Income Growth | 15.70% | 33.41% | -33.75% | -6.97% | 29.94% |
Shares Outstanding (Basic) | 682 | 582 | 582 | 582 | 583 |
Shares Outstanding (Diluted) | 682 | 582 | 582 | 582 | 583 |
Shares Change (YoY) | 17.09% | 0.05% | -0.10% | -0.11% | 7.38% |
EPS (Basic) | 0.83 | 0.84 | 0.63 | 0.95 | 1.02 |
EPS (Diluted) | 0.83 | 0.84 | 0.63 | 0.95 | 1.02 |
EPS Growth | -1.19% | 33.33% | -33.68% | -6.86% | 21.01% |
Free Cash Flow | - | -22.38 | -1,000 | -3,395 | -880.49 |
Free Cash Flow Per Share | - | -0.04 | -1.72 | -5.83 | -1.51 |
Dividend Per Share | - | 0.400 | 0.190 | 0.180 | 0.321 |
Dividend Growth | - | 110.53% | 5.56% | -43.99% | -43.75% |
Gross Margin | 19.27% | 28.28% | 27.40% | 33.97% | 35.42% |
Operating Margin | 19.27% | 12.30% | 7.83% | 16.66% | 21.12% |
Profit Margin | 17.17% | 16.53% | 17.34% | 22.66% | 25.16% |
Free Cash Flow Margin | - | -0.76% | -47.32% | -139.06% | -37.25% |
EBITDA | 951.01 | 679.85 | 451.26 | 671.73 | 667.79 |
EBITDA Margin | 28.86% | 22.98% | 21.34% | 27.52% | 28.25% |
D&A For EBITDA | 315.92 | 315.92 | 285.72 | 265.12 | 168.54 |
EBIT | 635.09 | 363.93 | 165.55 | 406.61 | 499.25 |
EBIT Margin | 19.27% | 12.30% | 7.83% | 16.66% | 21.12% |
Effective Tax Rate | 10.42% | 13.40% | 9.00% | 11.97% | 12.55% |
Revenue as Reported | - | 2,958 | 2,114 | 2,441 | 2,363 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.